Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE). Measure: Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs. Measure: Cohort 4: Change from baseline in serum and urine complement component levels.. After: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). Measure: Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. Measure: Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels..
Participant count type changed
Before: Estimated. After: Actual.
Enrollment · participant count changed
Before: 54 participants (planned). After: 31 participants (actual).
Completion date type changed
Before: Estimated. After: Actual.
Primary completion date changed
Before: Dec 2020. After: 25 Aug 2020.
Recruitment status changed
Before: Recruiting. After: Terminated.